Metaplasia gastrik Dokter Terbaik di Israel - TOP-7 dokter

Dr. Pelles Sharon adalah seorang ahli onkologi berkualifikasi tinggi yang berspesialisasi dalam bedah kanker lambung di Sourasky Medical Center (Ichilov).

• Melakukan penelitian klinis inovatif mengenai sikap pasien onkologi terhadap uji klinis
• Melakukan prosedur lanjutan seperti bedah HIPEC dan Whipple
• Terampil dalam perawatan kanker secara bedah maupun non-bedah

Spesialis dalam bedah perut terbuka maupun invasif minimal, termasuk prosedur Whipple yang kompleks. Ia mengepalai Departemen Bedah Kolorektal di Sourasky Medical Center (Ichilov).

• Lebih dari 20 tahun pengalaman bedah
• Ahli dalam teknik invasif minimal tingkat lanjut
• Kepala departemen, memimpin tim bedah khusus

Sebagai Kepala Pusat Kanker Gastrointestinal, Dr. Hubert memimpin unit khusus yang berfokus pada kanker pencernaan yang kompleks.

• 33 tahun pengalaman klinis dalam onkologi dan radioterapi
• Sertifikasi dewan ganda dalam onkologi dan radioterapi
• Dokter senior di Rumah Sakit Universitas Hadassah
• Anggota aktif Komite Israel untuk Kanker Gastrointestinal
• Pendidikan mencakup gelar dokter (M.D.) dan gelar psikologi

Dr. Yuri Goldes is a general surgeon with more than 20 years of clinical experience. He specializes in upper gastrointestinal and oncologic surgery. He is Deputy Director of the Department of General Surgery and Transplantation at Sheba Medical Center in Tel Aviv. He also leads the Upper GI Surgery Unit. He was named to Forbes Israel’s Best Doctors in 2025. He is ranked among Israel’s Best Gastrointestinal Surgeons by Forbes. In 2019, he received the Israeli Ministry of Health “Best Doctor of the Year” award.

He is an expert in advanced minimally invasive and robotic surgery. He treats diaphragmatic hernia, achalasia, GERD, and gallbladder disease. He also performs oncologic surgery for pancreatic, gastric, and esophageal cancers. He uses laparoscopic and robotic techniques.

He pioneered some of Israel’s first robotic oncologic resections of the stomach and pancreas. He is among a small group worldwide who perform minimally invasive Whipple procedures (pancreaticoduodenectomy) using advanced laparoscopy. He applies methods that improve outcomes and speed recovery. He provides personalized care.

Prof. Ben Boursi is a physician in the Gastrointestinal Cancer Department at Sheba Medical Center. He specializes in internal medicine, medical oncology, and cancer epidemiology. He is board certified in internal medicine and medical oncology. He earned a B.Med.Sc (summa cum laude) and an MD (magna cum laude) from Tel Aviv University.

He completed clinical and research fellowships in GI oncology and cancer epidemiology at the University of Pennsylvania. He also completed electives at MD Anderson and Mayo Clinic. He founded the ECOG-ACRIN Microbiome Working Group. His microbiome-oncology research has been published in leading journals, including Science, and highlighted by ASCO.

He developed predictive models for early diagnosis of colorectal and pancreatic cancers. These models are now in clinical evaluation. He holds an academic appointment at Tel Aviv University. He is also an Associate Scholar at the University of Pennsylvania.

Professor Raanan Berger, MD PhD, is a medical oncologist and radiotherapist. He is Director of the Cancer Center at Sheba Medical Center and heads its clinical research unit. He was listed in Forbes Israel’s “Best Doctors” (2025). He leads the genitourinary oncology program with a focus on prostate cancer. His care includes systemic therapy and radiotherapy in a multidisciplinary, patient-centered model.

He is board-certified in oncology. He earned his MD and PhD at Tel Aviv University and completed his clinical training at Sheba. He then completed a postdoctoral fellowship at Dana-Farber/Harvard, focusing on prostate cancer with Dr. Philip Kantoff and molecular oncology in Dr. William C. Hahn’s lab. He is a member of ESMO and ASCO. He has co-authored more than 20 peer-reviewed papers, including studies on outcomes in high- versus very high-risk prostate cancer and on BRCA1/2 in large cohorts.